![Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial | BMC Ophthalmology | Full Text Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial | BMC Ophthalmology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12886-015-0024-0/MediaObjects/12886_2015_24_Fig2_HTML.gif)
Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial | BMC Ophthalmology | Full Text
![Cryosurgery During Imiquimod Cream Treatment ("Immunocryosurgery") for Bowen's Disease of the Skin: A Case Series | HTML | Acta Dermato-Venereologica Cryosurgery During Imiquimod Cream Treatment ("Immunocryosurgery") for Bowen's Disease of the Skin: A Case Series | HTML | Acta Dermato-Venereologica](https://www.medicaljournals.se/acta/content_files/files/web/3249-web-images/3249fig1_opt.jpeg)
Cryosurgery During Imiquimod Cream Treatment ("Immunocryosurgery") for Bowen's Disease of the Skin: A Case Series | HTML | Acta Dermato-Venereologica
![Imiquimod in the treatment of eyelid basal cell carcinoma - Leppälä - 2007 - Acta Ophthalmologica Scandinavica - Wiley Online Library Imiquimod in the treatment of eyelid basal cell carcinoma - Leppälä - 2007 - Acta Ophthalmologica Scandinavica - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6a2a5914-a3ca-4390-af9c-69f314b766e5/aos_896_f1.gif)
Imiquimod in the treatment of eyelid basal cell carcinoma - Leppälä - 2007 - Acta Ophthalmologica Scandinavica - Wiley Online Library
![Twelve-week Treatment of Lentigo Maligna with Imiquimod Results in a High and Sustained Clearance Rate | HTML | Acta Dermato-Venereologica Twelve-week Treatment of Lentigo Maligna with Imiquimod Results in a High and Sustained Clearance Rate | HTML | Acta Dermato-Venereologica](https://www.medicaljournals.se/acta/content_files/files/web/4168-web-resources/image/9219.png)
Twelve-week Treatment of Lentigo Maligna with Imiquimod Results in a High and Sustained Clearance Rate | HTML | Acta Dermato-Venereologica
![The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation | Scientific Reports The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-017-16707-5/MediaObjects/41598_2017_16707_Fig1_HTML.jpg)
The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation | Scientific Reports
![Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology](https://cdn.mdedge.com/files/s3fs-public/styles/teaser_opengraph/public/images/article_teasers/CT095020020-e_fig1_carousel.jpg)
Imiquimod Induces Sustained Remission of Actinic Damage: A Case Report Spanning One Decade of Observation | MDedge Dermatology
![Oral Acitretin and Topical Imiquimod as Neoadjuvant Treatment for Giant Basal Cell Carcinoma | Actas Dermo-Sifiliográficas Oral Acitretin and Topical Imiquimod as Neoadjuvant Treatment for Giant Basal Cell Carcinoma | Actas Dermo-Sifiliográficas](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1578219012000625:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w91sAmkCw32Jed9sZf6jzEuDbFpW7G0NfARZs8afh+9K8v8RN+oFy2ZmalFHXVYo6AqyRe3Ot0eJsGZd0pYvOGIRQriFGT+m0opbS2dNZEPGEcDgzj3bgUCPHJ4EZqTELATlugiKx0AqZpjqtQEhkofl3WKFcYtxB9Y0Kq1bHTYsGkaq/YpL2zlO3HIpkUvoxUhuAEDaKFuIz+ijRrPRKaYEiOqMmz6t2VqrPAJIb+umTUnYb4xMaZlF9bqopApZiJ1cNRqKcFDVqjsz4CJYet64=)
Oral Acitretin and Topical Imiquimod as Neoadjuvant Treatment for Giant Basal Cell Carcinoma | Actas Dermo-Sifiliográficas
![A cutback in Imiquimod cutaneous toxicity; comparative cutaneous toxicity analysis of Imiquimod nanotransethosomal gel with 5% marketed cream on the BALB/c mice | Scientific Reports A cutback in Imiquimod cutaneous toxicity; comparative cutaneous toxicity analysis of Imiquimod nanotransethosomal gel with 5% marketed cream on the BALB/c mice | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-18671-1/MediaObjects/41598_2022_18671_Fig1_HTML.png)
A cutback in Imiquimod cutaneous toxicity; comparative cutaneous toxicity analysis of Imiquimod nanotransethosomal gel with 5% marketed cream on the BALB/c mice | Scientific Reports
![Using topical imiquimod for the management of positive in situ margins after melanoma resection - Pandit - 2015 - Cancer Medicine - Wiley Online Library Using topical imiquimod for the management of positive in situ margins after melanoma resection - Pandit - 2015 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c09474d0-6252-4a82-b95e-200bb5c82bc6/cam4402-fig-0002-m.jpg)
Using topical imiquimod for the management of positive in situ margins after melanoma resection - Pandit - 2015 - Cancer Medicine - Wiley Online Library
![Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial - The Lancet Oncology Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2021742740/2041575949/gr1.gif)